Zepp Health Corporation (ZEPP)
NYSE: ZEPP · Real-Time Price · USD
4.830
-0.370 (-7.12%)
At close: Jun 18, 2026, 4:00 PM EDT
4.740
-0.090 (-1.86%)
After-hours: Jun 18, 2026, 7:31 PM EDT

Zepp Health Earnings Call Transcripts

Fiscal Year 2026

  • Q1 2026 revenue rose 33.8% year-over-year to $51.5M, driven by premium product launches and a strong brand position in hybrid training. Gross margin expanded to 37.7% despite higher costs, and Q2 revenue is guided at $63–68M, with continued focus on profitable growth.

Fiscal Year 2025

  • Delivered strong revenue and margin growth in 2025, driven by premium product expansion and disciplined cost management. Guidance for Q1 2026 anticipates 30%-43% year-over-year revenue growth, with further margin improvement expected as premium mix scales.

  • Q3 2025 saw 78.5% revenue growth, operating break-even, and strong sales across premium and entry-level products. Gross margin improved sequentially, and Q4 revenue is guided up 38%-45% year-over-year, with robust product launches and continued margin expansion expected.

  • Revenue grew 46% YoY to $59.4M, driven by Amazfit brand and new product launches. Gross margin held at 36.2%, with Q3 revenue guidance of $72–$76M and margin expansion expected. Supply chain diversification and debt refinancing improved resilience.

  • Q1 2025 saw 10% year-over-year revenue growth, driven by strong Amazfit product sales and successful new launches. Gross margin improved to 37.3%, and Q2 revenue is projected to grow 23%-35% year-over-year, with continued cost control and supply chain diversification.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018